First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer

Thürlimann, B.; Beretta, K.; Bacchi, M.; Castiglione-Gertsch, M.; Goldhirsch, A.; Jungi, W. F.; Cavalli, F.; Senn, H.-J.; Fey, M.; Löhnert, T. (1996). First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Annals of oncology, 7(5), pp. 471-479. Oxford University Press 10.1093/oxfordjournals.annonc.a010635

[img]
Preview
Text
7-5-471.pdf - Published Version
Available under License Publisher holds Copyright.

Download (4MB) | Preview

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Castiglione, Monica and Fey, Martin

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0923-7534

Publisher:

Oxford University Press

Language:

English

Submitter:

Markus Müller

Date Deposited:

27 Sep 2018 14:21

Last Modified:

02 Nov 2019 16:00

Publisher DOI:

10.1093/oxfordjournals.annonc.a010635

BORIS DOI:

10.7892/boris.115807

URI:

https://boris.unibe.ch/id/eprint/115807

Actions (login required)

Edit item Edit item
Provide Feedback